from Reuters: Health News https://ift.tt/2IuhDmQ
Merck's Keytruda boosts response in hard-to-treat lung cancer
(Reuters) - The combination of Merck & Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday.
from Reuters: Health News https://ift.tt/2IuhDmQ
from Reuters: Health News https://ift.tt/2IuhDmQ
Subscribe to:
Post Comments (Atom)
-
The German cabinet will hold a secret session on Wednesday to discuss safeguard measures regarding the possible participation of China's...
-
Stocks poised for another day of gains Equity markets look to add to the gains from the prior session as investor concerns about the fu...
-
By LIAM STACK from NYT Magazine https://ift.tt/2FNPp6k
No comments:
Post a Comment